YEAR-END REPORT 2008 TRIPEP AB (PUBL)
• Research and development costs amounted to SEK 17.1 (21.3) m
• The loss after tax was SEK -24.9 (-32.7) m
• Earnings per share were SEK -2.29 (-5.59)
• Net sales SEK 3,8 (-) m
• The company carried out a private placement during the fourth quarter 2008 which raised SEK 5 m, and a rights issue which raised approx. SEK 4.9 m before transaction costs
• After an interim analysis of available study data in November the last three patients are enrolled for high-dose treatment in the ChronVac-C® study
• Tripep secured a US patent which is strengthening our position regarding ChronVac-C®
• Patent application filed for a new antibiotic-free formulation of ChronSeal® in collaboration with Kringle Pharma, Inc.
• Tripep has obtained an approval from the Norwegian Medical Products Agency to start the phase II study with ChronSeal® and the study started in January 2009
• Tripep secures financing in ChronSeal® through a new agreement with Kringle Pharma, Inc.
Events after the end of the reporting period
• Tripep has obtained an approval from the Swedish Medical Products Agency to start the phase II study with ChronSeal® and the study expects to start in Sweden in February 2009
• Through Tripep’s partner Kringle Pharma a letter of intent has been signed with the Japanese specialty pharma company Maruho regarding ChronSeal®
For more information, please contact:
Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, Mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se
Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se
About Tripep
Tripep develops drugs against chronic disease based on proprietary and other parties’ patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal® and a therapeutic vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company’s website: www.tripep.se.
In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.